however , enrollment in this clinical trial has been temporarily suspended due to issues internal to nci and unrelated to our technology . the progress and timeline for this trial , including the timeline for dosing patients , are under the control of the nci . we are developing chimeric antigen receptor , or car , t cell , or car+ t , therapies targeting cd19 on malignant b cells using our sleeping beauty platform . we are advancing our so-called rapid personalized manufacture , or rpm , technology , in greater china with eden biocell , ltd. , or eden biocell , our joint venture with triarm therapeutics , ltd. rpm enables small numbers of t cells to be infused as soon as the day after gene transfer which is made possible by the genetic modification of resting t cells to express car and membrane bound il-15 , or mbil15 . eden biocell is leading the clinical development and commercialization of sleeping beauty-generated cd19-specific rpm car+t therapies using patient-derived ( autologous ) t cells in order to treat patients with relapsed or refractory cd19+ leukemias and lymphomas . in the fourth quarter of 2020 , an ind was cleared by the taiwan fda for a phase 1 clinical trial designed to evaluate safety and efficacy in this patient group . in our phase 1 clinical trial being conducted in the united states , we plan to infuse donor-derived t cells after allogeneic bone marrow transplantation , or bmt , for recipients who have relapsed with cd19+ leukemias and lymphomas with our cd19- specific car+ t therapies manufactured using our technology . our controlled il-12 platform is based on an engineered replication-incompetent adenovirus , referred to as ad-rts-hil-12 , plus veledimex as a gene delivery system to conditionally produce il-12 , a potent , naturally occurring anti-cancer protein , to treat patients with solid tumors . our controlled il-12 platform allows us to deliver il-12 in a tunable dose as the cytokine is under transcriptional control of the rheoswitch therapeutic system ® ( rts ® ) . we have completed enrollment to all our phase 1 and 2 clinical trials of patients with recurrent glioblastoma multiforme , or rgbm . these trials examine the effect of controlled il-12 as a monotherapy and in combination with blockade of the immune checkpoint protein pd-1 . dosing is ongoing in a phase 2 clinical trial evaluating ad-rts-hil-12 plus veledimex in combination with pd1 antibody libtayo ® ( cemiplimab-rwlc ) for the treatment of recurrent or progressive glioblastoma multiforme in adults . data from our monotherapy and combination studies have been presented at major scientific conferences . as of december 31 , 2020 , we have approximately $ 115.1 million of cash and cash equivalents . given our current development plans , we anticipate our cash resources will be sufficient to fund our operations into the second quarter of 2022 , and we have no committed sources of additional capital at this time . the forecast of cash resources is forward-looking information that involves risks and uncertainties , and the actual amount of our expenses could vary materially and adversely as a result of a number of factors . we have based our estimates on assumptions that may prove to be wrong , and our expenses could prove to be significantly higher than we currently anticipate . management does not know whether additional financing will be on terms favorable or 75 acceptable to us when needed , if at all . if adequate additional funds are not available when required , or if we are unsuccessful in entering into partnership agreements for further development of our product candidates , management may need to curtail its development efforts and planned operations . our amended and restated certificate of incorporation authorizes us to issue 250,000,000 shares of common stock . as of february 24 , 2020 , there were 214,667,023 shares of common stock outstanding and an additional 31,115,329 shares of common stock reserved for issuance pursuant to outstanding stock options and warrants . though we have no immediate plans to issue additional shares of common stock , other than in connection with our 2020 equity incentive plan , we may need additional shares for business and financial purposes in the future . we have not generated significant revenue and have incurred significant net losses in each year since our inception . for the year ended december 31 , 2020 , we had a net loss of $ 80.0 million , and through december 31 , 2020 , we have incurred approximately $ 764.1 million of accumulated deficit since our inception in 2003. we expect to continue to incur significant operating expenditures and net losses . further development of our product candidates will likely require substantial increases in our expenses as we : continue to undertake clinical trials for product candidates ; seek regulatory approvals for product candidates ; work with regulatory authorities to identify and address program-related inquiries ; implement additional internal systems and infrastructure ; hire additional personnel ; and scale-up the formulation and manufacturing of our product candidates . we continue to seek additional financial resources to fund the further development of our product candidates . if we are unable to obtain sufficient additional capital , one or more of these programs could be delayed , and we may be unable to continue our operations at planned levels and be forced to reduce our operations . because of the numerous risks and uncertainties associated with product development , we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability . story_separator_special_tag the net cash used in operating activities for the year ended december 31 , 2020 was primarily a result of our net loss of $ 80.0 million , an increase in receivables of $ 1.3 million , an increase in other noncurrent assets of $ 0.6 million , offset by an decrease in prepaid expenses and other current assets of $ 11.6 million primarily related to the use of funds at md anderson and an increase in accounts payable and accrued expenses of $ 5.3 million . the net cash used in operating activities for the year ended december 31 , 2019 was primarily a result of our net loss of $ 117.8 million , an increase in receivables of $ 1.5 million , an increase in prepaid expenses and other current assets of $ 1.7 million , offset by a decrease in other noncurrent assets of $ 9.4 million , and an increase in accounts payable and accrued expenses of $ 1.9 million . net cash used in operating activities for the year ended december 31 , 2018 was primarily a result of our net loss of $ 53.1 million , an increase in receivables of $ 1.9 million , an increase of prepaid expenses and other current assets of $ 1.3 million , and a decrease in accounts payable and accrued expenses of $ 4.8 million , offset by a decrease of other noncurrent assets of $ 4.0 million . net cash used in investing activities was $ 9.8 million for the year ended december 31 , 2020 compared to $ 284 thousand and $ 459 thousand for the years ended december 31 , 2019 and december 31 , 2018 , respectively . the change was due primarily to increases in equipment purchases and leasehold improvements under our agreement with md anderson to build out space in houston , texas during the year ended december 31 , 2020. net cash provided by financing activities was $ 102.1 million for the year ended december 31 , 2020 compared to net cash provided by financing activities of $ 59.2 million and $ 40.3 million provided by financing activities for the years ended december 31 , 2019 and 2018 , respectively . the $ 102.1 million provided by financing activities during the year ended december 31 , 2020 , is a result of net proceeds of $ 88.7 million from the issuance of common stock in our follow-on public offering , net and $ 13.0 million from the issuance of common stock pursuant to our atm facility . the $ 59.2 million provided by financing activities during the year ended december 31 , 2019 is a result of net proceeds from the issuance of common stock upon exercise of warrants of $ 52.5 million , net proceeds from the issuance in connection with an at the market offering of $ 6.1 million , proceeds from the exercise of stock options of $ 1.2 million , offset by $ 0.7 million used to repurchase common stock . the $ 40.3 million provided by financing activities during the year ended december 31 , 2018 is a result of net proceeds of $ 47.1 million from our november 2018 financing which were offset by cash paid of $ 5.4 million from our license agreement and $ 1.6 million paid for the repurchase of common stock . operating capital and capital expenditure requirements we anticipate that losses will continue for the foreseeable future . at december 31 , 2020 , our accumulated deficit was approximately $ 764.1 million . our actual cash requirements may vary materially from those planned because of a number of factors including : changes in the focus , direction and pace of our development programs ; competitive and technical advances ; costs associated with the development of our product candidates ; our ability to secure partnering arrangements ; costs of filing , prosecuting , defending and enforcing any patent claims and any other intellectual property rights , or other developments ; and other matters identified under part i – item 1a . “ risk factors . ” 83 working capital as of december 31 , 2020 was $ 112.2 million , consisting of $ 130.6 million in current assets and $ 18.4 million in current liabilities . working capital as of december 31 , 2019 was $ 93.0 million , consisting of $ 105.5 million in current assets and $ 12.5 million in current liabilities . contractual obligations the following table summarizes our outstanding obligations as of december 31 , 2020 and the effect those obligations are expected to have on our liquidity and cash flows in future periods : replace_table_token_6_th our commitments for operating leases relate to the lease for our corporate headquarters in boston , massachusetts , and laboratory and office space in houston , texas . on december 21 , 2015 and april 15 , 2016 , we renewed the sublease for our corporate headquarters in boston , ma through august 31 , 2021. on january 30 , 2018 , we entered into a lease agreement for office space in houston , tx at md anderson through april 2021. on march 12 , 2019 , we entered into a lease agreement for additional office space in houston through april 2021. on october 15 , 2019 , we entered into another lease agreement for additional office space in houston through february 2027. on april 13 , 2020 , we entered into another lease agreement for additional office and laboratory space in houston through february 2027. on june 1 , 2020 , we entered into a short-term lease in houston for office and laboratory space . on september 1 , 2020 , we entered an additional short-term lease in houston for additional office and laboratory space . on december 15 , 2020 , we entered into another lease for additional office and laboratory space in houston through april 2028. on january 10 , 2017 , we announced the signing of

sources of liquidity to date , we have financed our operations primarily through public offerings of our common stock , private placements of our convertible equity securities and collaborations . through december 31 , 2020 , we have received an aggregate of $ [ ● ] from public offerings and through our “ at-the-market ” offering program . liquidity and capital resources as of december 31 , 2020 , we have approximately $ 115.1 million of cash and cash equivalents . given our current development plans , in addition to our recent financing , we anticipate cash resources will be sufficient to fund our operations into the second quarter of 2022 , and we have no committed sources of additional capital at this time . the forecast of cash resources is forward-looking information that involves risks and uncertainties , and the actual amount of our expenses could vary materially and adversely as a result of a number of factors . we have based our estimates on assumptions that may prove to be wrong , and our expenses could prove to be significantly higher than we currently anticipate . management does not know whether additional financing will be on terms favorable or acceptable to us when needed , if at all . if adequate additional funds are not available when required , or if we are unsuccessful in entering into partnership agreements for further development of our products , management may need to curtail development efforts . 80 in addition to these factors , our actual cash requirements may vary materially from our current expectations for a number of other factors that may include , but are not limited to , changes in the focus and direction of our development programs , competitive and technical advances , costs associated with the development of our product candidates , our ability to secure partnering arrangements , and the costs of filing , prosecuting , defending and enforcing our intellectual property rights .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```sources of liquidity to date , we have financed our operations primarily through public offerings of our common stock , private placements of our convertible equity securities and collaborations . through december 31 , 2020 , we have received an aggregate of $ [ ● ] from public offerings and through our “ at-the-market ” offering program . liquidity and capital resources as of december 31 , 2020 , we have approximately $ 115.1 million of cash and cash equivalents . given our current development plans , in addition to our recent financing , we anticipate cash resources will be sufficient to fund our operations into the second quarter of 2022 , and we have no committed sources of additional capital at this time . the forecast of cash resources is forward-looking information that involves risks and uncertainties , and the actual amount of our expenses could vary materially and adversely as a result of a number of factors . we have based our estimates on assumptions that may prove to be wrong , and our expenses could prove to be significantly higher than we currently anticipate . management does not know whether additional financing will be on terms favorable or acceptable to us when needed , if at all . if adequate additional funds are not available when required , or if we are unsuccessful in entering into partnership agreements for further development of our products , management may need to curtail development efforts . 80 in addition to these factors , our actual cash requirements may vary materially from our current expectations for a number of other factors that may include , but are not limited to , changes in the focus and direction of our development programs , competitive and technical advances , costs associated with the development of our product candidates , our ability to secure partnering arrangements , and the costs of filing , prosecuting , defending and enforcing our intellectual property rights .
```    
 Suspicious Activity Report : however , enrollment in this clinical trial has been temporarily suspended due to issues internal to nci and unrelated to our technology . the progress and timeline for this trial , including the timeline for dosing patients , are under the control of the nci . we are developing chimeric antigen receptor , or car , t cell , or car+ t , therapies targeting cd19 on malignant b cells using our sleeping beauty platform . we are advancing our so-called rapid personalized manufacture , or rpm , technology , in greater china with eden biocell , ltd. , or eden biocell , our joint venture with triarm therapeutics , ltd. rpm enables small numbers of t cells to be infused as soon as the day after gene transfer which is made possible by the genetic modification of resting t cells to express car and membrane bound il-15 , or mbil15 . eden biocell is leading the clinical development and commercialization of sleeping beauty-generated cd19-specific rpm car+t therapies using patient-derived ( autologous ) t cells in order to treat patients with relapsed or refractory cd19+ leukemias and lymphomas . in the fourth quarter of 2020 , an ind was cleared by the taiwan fda for a phase 1 clinical trial designed to evaluate safety and efficacy in this patient group . in our phase 1 clinical trial being conducted in the united states , we plan to infuse donor-derived t cells after allogeneic bone marrow transplantation , or bmt , for recipients who have relapsed with cd19+ leukemias and lymphomas with our cd19- specific car+ t therapies manufactured using our technology . our controlled il-12 platform is based on an engineered replication-incompetent adenovirus , referred to as ad-rts-hil-12 , plus veledimex as a gene delivery system to conditionally produce il-12 , a potent , naturally occurring anti-cancer protein , to treat patients with solid tumors . our controlled il-12 platform allows us to deliver il-12 in a tunable dose as the cytokine is under transcriptional control of the rheoswitch therapeutic system ® ( rts ® ) . we have completed enrollment to all our phase 1 and 2 clinical trials of patients with recurrent glioblastoma multiforme , or rgbm . these trials examine the effect of controlled il-12 as a monotherapy and in combination with blockade of the immune checkpoint protein pd-1 . dosing is ongoing in a phase 2 clinical trial evaluating ad-rts-hil-12 plus veledimex in combination with pd1 antibody libtayo ® ( cemiplimab-rwlc ) for the treatment of recurrent or progressive glioblastoma multiforme in adults . data from our monotherapy and combination studies have been presented at major scientific conferences . as of december 31 , 2020 , we have approximately $ 115.1 million of cash and cash equivalents . given our current development plans , we anticipate our cash resources will be sufficient to fund our operations into the second quarter of 2022 , and we have no committed sources of additional capital at this time . the forecast of cash resources is forward-looking information that involves risks and uncertainties , and the actual amount of our expenses could vary materially and adversely as a result of a number of factors . we have based our estimates on assumptions that may prove to be wrong , and our expenses could prove to be significantly higher than we currently anticipate . management does not know whether additional financing will be on terms favorable or 75 acceptable to us when needed , if at all . if adequate additional funds are not available when required , or if we are unsuccessful in entering into partnership agreements for further development of our product candidates , management may need to curtail its development efforts and planned operations . our amended and restated certificate of incorporation authorizes us to issue 250,000,000 shares of common stock . as of february 24 , 2020 , there were 214,667,023 shares of common stock outstanding and an additional 31,115,329 shares of common stock reserved for issuance pursuant to outstanding stock options and warrants . though we have no immediate plans to issue additional shares of common stock , other than in connection with our 2020 equity incentive plan , we may need additional shares for business and financial purposes in the future . we have not generated significant revenue and have incurred significant net losses in each year since our inception . for the year ended december 31 , 2020 , we had a net loss of $ 80.0 million , and through december 31 , 2020 , we have incurred approximately $ 764.1 million of accumulated deficit since our inception in 2003. we expect to continue to incur significant operating expenditures and net losses . further development of our product candidates will likely require substantial increases in our expenses as we : continue to undertake clinical trials for product candidates ; seek regulatory approvals for product candidates ; work with regulatory authorities to identify and address program-related inquiries ; implement additional internal systems and infrastructure ; hire additional personnel ; and scale-up the formulation and manufacturing of our product candidates . we continue to seek additional financial resources to fund the further development of our product candidates . if we are unable to obtain sufficient additional capital , one or more of these programs could be delayed , and we may be unable to continue our operations at planned levels and be forced to reduce our operations . because of the numerous risks and uncertainties associated with product development , we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability . story_separator_special_tag the net cash used in operating activities for the year ended december 31 , 2020 was primarily a result of our net loss of $ 80.0 million , an increase in receivables of $ 1.3 million , an increase in other noncurrent assets of $ 0.6 million , offset by an decrease in prepaid expenses and other current assets of $ 11.6 million primarily related to the use of funds at md anderson and an increase in accounts payable and accrued expenses of $ 5.3 million . the net cash used in operating activities for the year ended december 31 , 2019 was primarily a result of our net loss of $ 117.8 million , an increase in receivables of $ 1.5 million , an increase in prepaid expenses and other current assets of $ 1.7 million , offset by a decrease in other noncurrent assets of $ 9.4 million , and an increase in accounts payable and accrued expenses of $ 1.9 million . net cash used in operating activities for the year ended december 31 , 2018 was primarily a result of our net loss of $ 53.1 million , an increase in receivables of $ 1.9 million , an increase of prepaid expenses and other current assets of $ 1.3 million , and a decrease in accounts payable and accrued expenses of $ 4.8 million , offset by a decrease of other noncurrent assets of $ 4.0 million . net cash used in investing activities was $ 9.8 million for the year ended december 31 , 2020 compared to $ 284 thousand and $ 459 thousand for the years ended december 31 , 2019 and december 31 , 2018 , respectively . the change was due primarily to increases in equipment purchases and leasehold improvements under our agreement with md anderson to build out space in houston , texas during the year ended december 31 , 2020. net cash provided by financing activities was $ 102.1 million for the year ended december 31 , 2020 compared to net cash provided by financing activities of $ 59.2 million and $ 40.3 million provided by financing activities for the years ended december 31 , 2019 and 2018 , respectively . the $ 102.1 million provided by financing activities during the year ended december 31 , 2020 , is a result of net proceeds of $ 88.7 million from the issuance of common stock in our follow-on public offering , net and $ 13.0 million from the issuance of common stock pursuant to our atm facility . the $ 59.2 million provided by financing activities during the year ended december 31 , 2019 is a result of net proceeds from the issuance of common stock upon exercise of warrants of $ 52.5 million , net proceeds from the issuance in connection with an at the market offering of $ 6.1 million , proceeds from the exercise of stock options of $ 1.2 million , offset by $ 0.7 million used to repurchase common stock . the $ 40.3 million provided by financing activities during the year ended december 31 , 2018 is a result of net proceeds of $ 47.1 million from our november 2018 financing which were offset by cash paid of $ 5.4 million from our license agreement and $ 1.6 million paid for the repurchase of common stock . operating capital and capital expenditure requirements we anticipate that losses will continue for the foreseeable future . at december 31 , 2020 , our accumulated deficit was approximately $ 764.1 million . our actual cash requirements may vary materially from those planned because of a number of factors including : changes in the focus , direction and pace of our development programs ; competitive and technical advances ; costs associated with the development of our product candidates ; our ability to secure partnering arrangements ; costs of filing , prosecuting , defending and enforcing any patent claims and any other intellectual property rights , or other developments ; and other matters identified under part i – item 1a . “ risk factors . ” 83 working capital as of december 31 , 2020 was $ 112.2 million , consisting of $ 130.6 million in current assets and $ 18.4 million in current liabilities . working capital as of december 31 , 2019 was $ 93.0 million , consisting of $ 105.5 million in current assets and $ 12.5 million in current liabilities . contractual obligations the following table summarizes our outstanding obligations as of december 31 , 2020 and the effect those obligations are expected to have on our liquidity and cash flows in future periods : replace_table_token_6_th our commitments for operating leases relate to the lease for our corporate headquarters in boston , massachusetts , and laboratory and office space in houston , texas . on december 21 , 2015 and april 15 , 2016 , we renewed the sublease for our corporate headquarters in boston , ma through august 31 , 2021. on january 30 , 2018 , we entered into a lease agreement for office space in houston , tx at md anderson through april 2021. on march 12 , 2019 , we entered into a lease agreement for additional office space in houston through april 2021. on october 15 , 2019 , we entered into another lease agreement for additional office space in houston through february 2027. on april 13 , 2020 , we entered into another lease agreement for additional office and laboratory space in houston through february 2027. on june 1 , 2020 , we entered into a short-term lease in houston for office and laboratory space . on september 1 , 2020 , we entered an additional short-term lease in houston for additional office and laboratory space . on december 15 , 2020 , we entered into another lease for additional office and laboratory space in houston through april 2028. on january 10 , 2017 , we announced the signing of

